In article <4uitdo$nj7 at newsbf02.news.aol.com>, SNOWTREK
<mailto:snowtrek at aol.com> wrote:
>> First 2 responses: Yeah, but my purpose is a standardized, quantitatively
> well-characterized assessment of this anti-CD3 mab's binding. I need to be
> able to walk over to the incubator and pull out a T-175 full of cell XYZ,
> grab a quarter million, mix in the mab, and get reasonable reproducibility
> in response. The variability and poor characterization of PBLs (possible
> pathogen present?, etc) makes them a non-viable alternative. Third
> response: The Jurkats didn't work for me. As you suggest, recloning them
> might allow isolation of a CD3 dense, homogeneous poulation. And, I'll
> look into the Molt16s. THANKS for the replies!!!!
>Uhm,
Very interesting, do I detect from this request that we may be seeing
a replacement for that well used mouse antibody OKT3 appearing soon?
There are of course several humanised CD3 antibodies around including
humanised OKT-3 which has been sitting in the freezer since Celltech
finished it several years ago.
Mike Clark, mrc7 at cam.ac.ukhttp://www.path.cam.ac.uk/~mrc7/
--
o/ \\ // || ,_ o Dr. M.R. Clark, Division of Immunology
<\__,\\ // __o || / /\, Cambridge University, Dept. Pathology
"> || _`\<,_ // \\ \> | Tennis Court Rd., Cambridge CB2 1QP
` || (_)/ (_) // \\ \_ Tel. 01223 333705 Fax. 01223 333875
